Deal Announcement 1/23: Healthcare

PwC acted as exclusive financial advisor to the private shareholders on the sale of Curanosticum MVZ GmbH, a leading German Clinic for Nuclear Medicine, to RAD-x Management GmbH

The Deal

The PwC M&A team is pleased to announce the successful sale of Curanosticum MVZ GmbH (“Curanosticum”) to RAD-x Management GmbH (“RAD-x”). PwC M&A acted as exclusive financial advisor to the private shareholders of Curanosticum. Curanosticum is a leading German Clinic for Nuclear Medicine and pioneer in THERANOSTICS. The acquisition allows RAD-x to significantly expand its expertise in the field of high-end Nuclear Medicine and expand its radiology clinic network to the Rhine-Main area.

The share purchase agreement was signed in August 2022 and the transaction was closed in January 2023.

Curanosticum MVZ GmbH (“Target”)

Curanosticum is a leading German Clinic for Nuclear Medicine and a pioneer in THERANOSTICS, a highly modern application in Nuclear Medicine which combines PET/CT-diagnostics with molecular radiotherapies. The clinic serves national and international patients at its two sites in Wiesbaden and Frankfurt. In addition, to profiting from contracts with numerous regional hospitals and outpatient care tumor centers, Curanosticum closely cooperates with the DKD Helios hospital in Wiesbaden. The clinic offers state-of-the-art medical equipment, including two 128-line PET/CT devices, and operates an in-house radiochemical laboratory. The experienced and well-trained medical staff comprises 11 physicians with specializations in Nuclear Medicine and Radiology.

RAD-x Management GmbH (“Buyer”)

RAD-x is one of the leading European diagnostic imaging clinic operators. Since its inception in 2016 RAD-x has successfully grown to a leading operator with 23 sites, 115 doctors and 700 staff across Germany and Switzerland. RAD-x invests strongly in the clinics that have joined its network, supports best practices sharing across its centers and assists the clinics with general management services including digitalization, procurement, finance, recruitment, hospital partnerships and site development. In addition, the company offers teleradiology services to support hospitals and diagnostic imaging groups with overload and emergency diagnostic services.


The global PricewaterhouseCoopers network is a worldwide association of independent auditing and consulting companies which together employ almost 328,000 people in 152 countries. Our global network comprises over 2,900 M&A professionals all over the world, realising approx. 400 successful transactions per year. We specialise in a wide range of independent M&A services including advice on acquisitions and disposals, mergers, public takeovers, privatisations as well as structured financing.

PwC M&A Germany acted as exclusive financial advisor to the shareholders of Curanosticum. The transaction was led by Alexander von Friesen (Partner) and supported by Nils Kaufmann (Associate) and Ibrahim Günal (Associate).

Contact us

Dr. Alexander von Friesen

Dr. Alexander von Friesen

Partner, Corporate Finance | M&A Healthcare & Consumer, PwC Germany

Tel: +49 151 11714398

Follow us